6月3日 - 生物技术公司 Celcuity Inc. 宣布,已为其增发的2032年到期、利率为0.250%的可转换优先票据完成定价。此次发行规模最终确定为5亿美元。
该笔票据的发行规模较原计划有所扩大,凸显了市场对其融资条款的认可。可转换票据为投资者提供了未来将债务转换为公司股权的选择权,是成长型公司常见的融资工具之一。
6月3日 - 生物技术公司 Celcuity Inc. 宣布,已为其增发的2032年到期、利率为0.250%的可转换优先票据完成定价。此次发行规模最终确定为5亿美元。
该笔票据的发行规模较原计划有所扩大,凸显了市场对其融资条款的认可。可转换票据为投资者提供了未来将债务转换为公司股权的选择权,是成长型公司常见的融资工具之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.